5. Conclusion
These findings indicate the possible potential of GLP based therapy, as an add-on therapy to sulfasalazine in ameliorating IBD in A-A model of IBD in mice through regulating the secretion of the transcription factor NFκB- dependent inflammatory cytokines, decreasing the oxidative stress injury, promoting tissue repair of injured epithelium with better tolerated side effects. However, further long-term studies to evaluate the tolerability and efficacy of these drugs are required and the decision to choose any of these drugs should be tailored according to the general status of each patient and the presence of any compelling indication or contraindication.